Cancer News and Research

Latest Cancer News and Research

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009

Poniard Pharmaceuticals to present its corporate overview

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 2009 UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 3:00 p.m. Eastern Time at the Grand Hyatt Hotel in New York City.

16 Sep 2009

KemPharm announces nomination of its second pipeline candidate

KemPharm, Inc. today announced the nomination of its second pipeline candidate, KP201, based on its proprietary ligand activated therapy (LAT) platform. KP201 is a new chemical entity (NCE) for the treatment of pain with the possibility of reduced abuse potential. KP201 joins lead candidate KP106, which is a novel prodrug candidate in development for ADHD.

16 Sep 2009

Children's Hospital enrolls patients for ExCell clinical study

Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for the ExCell study. Children's Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children's centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel.

16 Sep 2009

PCEC to provide free prostate cancer screenings

This September, the Prostate Conditions Education Council reminds men to set aside 10 minutes to take lifesaving measures. In just 10 minutes, the same amount of time it takes to shave their faces, men can be screened for prostate cancer, the second leading cause of death among American men. For one week this month the Prostate Conditions Education Council (PCEC) will be coordinating Prostate Cancer Awareness Week (PCAW), which provides free or low-cost screenings to thousands of men across the United States.

16 Sep 2009

Premion commences cancer treatment with Varian's RapidArc radiotherapy technology

Cancer patients in Australia have gained access to advanced RapidArc(R) radiotherapy treatments from Varian Medical Systems (NYSE: VAR) with its introduction by the leading radiation oncology provider in Queensland. Premion, which operates five cancer centers in Queensland, has treated more than a dozen prostate cancer patients to date with this fast, precise and efficient technique at its Chermside treatment center in Brisbane.

16 Sep 2009

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the launch of genomic analysis tools that will help researchers in studies that associate genetic variation with specific diseases. These new tools, known as the MeltDoctor™ High-Resolution Melt (HRM) Reagents, are for research use only and are part of a PCR-based workflow that enables researchers to cost-effectively scan DNA from a variety of biological sample types to detect the smallest genetic variations among samples.

16 Sep 2009

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.

16 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Celsion's DIGNITY clinical trial aired on Good Morning America

Celsion Corporation announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.

16 Sep 2009

Aptuit obtains the CEO Cancer Gold Standard accreditation

Aptuit, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

16 Sep 2009

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

16 Sep 2009

GENova in advanced negotiations to acquire patents from TheraGlass

GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

16 Sep 2009

Pan American Health Organization calls for preventing sickness to curtail health care costs

According to every major health organization, many costly and disabling conditions such as cardiovascular disease, cancer, diabetes and chronic infectious diseases are linked by common preventable risk factors -- smoking, poor dietary habits, physical inactivity and poor hygiene.

16 Sep 2009

Albumin for cancer treatment

Tiny particles of albumin, a protein found in the blood, can be used to carry radioactive isotopes to the site of a cancerous tumour in the body and so avoid many of the side-effects of conventional radiotherapy.

16 Sep 2009

IntrinsiQ's first IntelliView 360 research study results released

IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360 research study. The biggest outcome: Oncologists believe they treat lung cancer patients in the maintenance setting three times more often than they actually do.

16 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

A Toll-like receptor (TLR) agonist, called imiquimod, which activates dendritic cells, is in clinical use as a topical application for basal cell carcinoma. In addition, a number of TLR agonists have been evaluated in clinical trials as an adjuvant for cancer vaccines.

16 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009

Research study investigates survival rates of prostate cancer patients across time periods

New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.

16 Sep 2009

Cancer News and Research

Latest Cancer News and Research

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Poniard Pharmaceuticals to present its corporate overview

KemPharm announces nomination of its second pipeline candidate

Children's Hospital enrolls patients for ExCell clinical study

PCEC to provide free prostate cancer screenings

Premion commences cancer treatment with Varian's RapidArc radiotherapy technology

Applied Biosystems launches MeltDoctor High-Resolution Melt Reagents for scanning DNA

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

Celsion's DIGNITY clinical trial aired on Good Morning America

Aptuit obtains the CEO Cancer Gold Standard accreditation

Santaris Pharma establishes its operations in the U.S.

GENova in advanced negotiations to acquire patents from TheraGlass

Pan American Health Organization calls for preventing sickness to curtail health care costs

Albumin for cancer treatment

IntrinsiQ's first IntelliView 360 research study results released

Legislation grants improve research and employment initiatives in Indiana University medical campus

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

Six research project grants aimed at improving human health awarded

Research study investigates survival rates of prostate cancer patients across time periods

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in